Knowledge Base

How to calculate the extension of SPC protection time?

26 December 2023
2 min read

The Supplementary Protection Certificate (SPC) provides a maximum protection period of up to 5 years, primarily aimed at compensating for the loss of patent protection time due to the time taken for the authorization of marketing by regulatory agencies. When calculating the duration of SPC protection, the filing date of the basic patent and the date of approval for the first marketing authorization should be taken into consideration:

If the first marketing authorization is obtained within 5 years of the basic patent filing date, no SPC protection period is granted.

If the first marketing authorization is obtained between 5 and 10 years after the basic patent filing date, the SPC protection period extends until 15 years after the date of the first marketing authorization.

If the first marketing authorization is obtained more than 10 years after the basic patent filing date, the SPC protection will last for 5 years from the date of patent expiry.

The specific formula for calculating the SPC protection period is "the date of the first marketing authorization grant - the filing date of the basic patent - 5 years". If the resulting duration is less than 0, no SPC protection is provided. If the period is less than 5 years, then that is the duration of the SPC protection. If the calculated duration is more than 5 years, a protection period of 5 years is provided.

Exploring Sintilimab's R&D successes and its clinical results at the 2023 ESMO_ASIA
ESMO 2023
4 min read
Exploring Sintilimab's R&D successes and its clinical results at the 2023 ESMO_ASIA
25 December 2023
On 2 Dec 2023, the latest clinical trial about Sintilimab in combination with anlotinib in 2023 ESMO_ASIA further demonstrated the therapeutic benefits.
Read →
What are TYK2 inhibitors and how do you quickly get the latest development progress?
What are TYK2 inhibitors and how do you quickly get the latest development progress?
25 December 2023
Selecting TYK2 inhibitors can reduce the inhibition of other immune-related pathways in the body, reduce the risk of infection, and be safer in clinical practice.
Read →
Travere Therapeutics starts key Phase 3 trial of Pegtibatinase for Classical Homocystinuria (HCU) management
Latest Hotspot
3 min read
Travere Therapeutics starts key Phase 3 trial of Pegtibatinase for Classical Homocystinuria (HCU) management
25 December 2023
Travere Therapeutics has begun a critical Phase 3 study of Pegtibatinase in the management of Classical Homocystinuria (HCU).
Read →
Does the divided dose of yellow fever vaccine present a greater risk of adverse reactions?
Knowledge Base
2 min read
Does the divided dose of yellow fever vaccine present a greater risk of adverse reactions?
25 December 2023
The fractional dose comes from the same full dose vaccine. It has been given to millions of people to prevent yellow fever in the past.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.